Objective: We retrospectively investigated the effects of adding HCQ 400 mg in patients with type 2 diabetes showing sub-optimal control by basal insulin and other OHA therapy.

Method: This is an open label, parallel group, retrospective and multicentre observational study. 123 patients with poorly controlled type 2 diabetes (baseline HbA1c 8.5 ± 0.6%) who are on basal insulin (glargine) with other OHA therapy (metformin 1gm+Sitagliptin 100 mg), were given HCQ 400 mg in addition to insulin. FPG, PPG and HbA1c values, daily insulin dose, body weight and the number of hypoglycemic events were recorded at weeks 0, 12 and 24.

Result: HbA1c decreased by 1.6%, from 8.5 ± 0.6% to 6.9 ± 0.8% (P<0.0001) at 24 weeks. FPG and PPG was reduced significantly from 223.7 ± 31 to 121± 19 mg/dl and from 313.2 ± 41 to 161± 21 mg/dl at the end of 24 week (P<0.0001). Required insulin dose was reduced significantly from 29.4 ± 14.5 to 22.1 ± 12.1 units/day (P= 0.0187). Body weight decreased significantly from 69.5 ± 5.2 to 67.0 ± 6.7 kg, (P= 0.0232). Numbers of hypoglycemic events per patient per month were 0.25 ± 0.35. No severe hypoglycemia occurred during the study period. 56% patients achieved HbA1c ≤ 7% at 24 weeks.

Conclusion: Administration of HCQ 400 mg resulted in sustained improvement in glycemic control when given as an adjunct to insulin therapy in patients with poorly controlled type 2 diabetes.


R. Ahmed: None. A. Sharma: None. A. Natarajan: None. D. Agarwal: None. A. Narayanan: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.